Posted on

Clonmel Healthcare is delighted to announce the launch of Lenalidomide Clonmel 5mg, 10mg, 15mg, 20mg, 25mg hard capsules. 

Lenalidomide Clonmel is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma and follicular lymphoma. 

Lenalidomide is structurally related to thalidomide, which is a known human teratogen that causes severe life-threatening birth defects. An unborn child is likely to be harmed if exposed to lenalidomide during pregnancy, therefore a pregnancy prevention programme (PPP) is in place for all lenalidomide products and applies to all patients prescribed lenalidomide. 

In order to support HCPs in fulfilling the requirements of the lenalidomide PPP, Clonmel Healthcare, in collaboration with a number of other marketing authorisations holders, has created an online platform called the Patient Safety Hub (PSH) which may be used by prescribers and pharmacies. It is available at 

Pharmacies wishing to purchase and dispense Lenalidomide Clonmel must register via the Patient Safety Hub at Registration involves the pharmacy indicating its agreement and compliance with the requirements of the lenalidomide pregnancy prevention programme. 

A user guide and training videos on use of the PSH are also available to access via the hub. 

Full prescribing information is available on request or alternatively, please go to http://www.clonmel-health. ie. Medicinal product subject to medical prescription. 

Please contact Clonmel Healthcare on 01-6204000 if you require any additional information. 

PA 126/320/002, 004-007. PA Holder: Clonmel Healthcare Ltd, Clonmel, Co Tipperary. Date prepared: February 2022. 2022/ADV/LEN/031H.